The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review감염, 중증도, 입원 및 사망률 감소에 대한 COVID-19 백신의 효능 및 효과: 체계적인 검토Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 변종, [키워드] accelerated approved B.1.1.7 B.1.351 B.1.351 variants COVID-19 COVID-19 pandemic COVID-19 vaccine COVID-19 vaccines database disease transmission effective Effectiveness Efficacy effort growth Hospitalization identify inclusion criteria Infection infections Mortality Pfizer Pfizer/BioNTech populations reduced reducing regimen required Seven severity systematic literature search systematic review Vaccine Vaccine development vaccine. Vaccines variants was performed [DOI] 10.1080/21645515.2022.2027160 PMC 바로가기 [Article Type] Article
A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & JohnsonSARS-CoV-2 백신에 대한 포괄적인 검토: Pfizer, Moderna & Johnson & JohnsonReview Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 변종, [키워드] Adenovirus administration age approval clinical clinical trial clinical trials coronavirus coronavirus. COVID-19 COVID-19 vaccine COVID-19 vaccines effective Efficacy General population group Johnson Johnson & Johnson Johnson & large cohort mechanism moderate Moderna mRNA vaccines Novel coronavirus ongoing trial ongoing trials outbreak pandemic participant Pfizer Safety SARS-CoV-2 SARS-CoV-2 coronavirus SARS-COV-2 infection shown Side effects Spike protein symptomatic SARS-CoV-2 infection tested the SARS-CoV-2 the spike protein the United State Trial United States Vaccinations Vaccine vaccine administration variant [DOI] 10.1080/21645515.2021.2002083 PMC 바로가기 [Article Type] Review
Review of SARS-CoV-2 Antigen and Antibody Testing in Diagnosis and Community SurveillanceReview Published on 2022-12-012023-07-10 Journal: Clinics in laboratory medicine [Category] COVID19(2023년), [키워드] antibody Antigen COVID-19 Moderna Pfizer SARS-CoV-2 serology vaccine. [DOI] 10.1016/j.cll.2022.09.018 PMC 바로가기 [Article Type] Review
Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkersArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 바이오마커, 변종, 진단, [키워드] AstraZeneca Biomarker booster case-control study caused Chronic diseases Clinical severity conducted country COVID-19 COVID-19 confirmed patient COVID-19 patient COVID-19 vaccination COVID-19 vaccine CRP level Delta delta variant Delta wave dose doses effective Effectiveness Efficacy expressed females Health homologous homologous vaccination. hospital Hospitalization Hospitalized individual infected with SARS-CoV-2 Iraq Lower males molecular no significant difference no significant effect omicron Omicron variant pandemic Patient patients Pfizer Population Prevent recommendation recorded risk SARS-CoV-2 SARS-CoV-2 pandemic SARS-CoV-2 variant severity significantly Symptom the disease the vaccine transmissibility of SARS-CoV-2 vaccination Vaccine variant variants of concern virus VOCs was done WBC [DOI] 10.1002/jmv.28098 PMC 바로가기
COVID-19 vaccine breakthrough infection among fully vaccinated healthcare workers in Duhok governorate, Iraqi Kurdistan: A retrospective cohort studyArticle Published on 2022-11-012022-11-16 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, [키워드] association Break through infections Breakthrough infection COVID-19 COVID-19 vaccine dentist determine Duhok effective Effectiveness enrolled females fill out fully vaccination HCW HCWs healthcare healthcare worker Healthcare workers highest incidence Infection infections Iraqi Kurdistan majority male Mild moderate MOST multicenter omicron outcomes paramedics participant Pfizer polymerase chain positive postvaccination prevaccination questionnaire random respiratory retrospective cohort study risk factor SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant severity significantly the disease the vaccine Vaccine vaccine effectiveness. variant was performed [DOI] 10.1002/jmv.27985 PMC 바로가기
Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosisArticle Published on 2022-11-012022-11-16 Journal: Journal of hepatology [Category] SARS, 변종, [키워드] 95% CI appear B.1.1.529 B.1.617.2 BNT BNT162b2 BNT162b2 mRNA booster booster dose chronic liver disease cirrhosis compensated Control control group COVD-19 COVID-19 COVID-19 in patient COVID-19 vaccines COVID-19-related death Critical dose doses General population greater hepatic decompensation hyporesponsiveness immune dysregulation liver magnitude moderate Moderate COVID-19 Moderna mRNA-1273 vaccine mRNA vaccine mRNA-1273 mRNA-1273. outcome overcome participant Patient Pfizer predominant receipt reduction in retrospective cohort study risk of infection Support symptomatic the vaccine Vaccine Vaccines variants veteran with COVID-19 [DOI] 10.1016/j.jhep.2022.07.036 PMC 바로가기
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control studyArticle Published on 2022-11-012022-11-15 Journal: The Lancet. Gastroenterology & Hepatology [Category] SARS, 진단, [키워드] adjusted age All participant anti-SARS-CoV-2 anti-TNF antibody Antibody binding antibody concentration Antibody concentrations approved available data boost booster case-control study combination therapy Concentration control group COVID-19 COVID-19 vaccine Diagnosis disease dose Evidence first dose geometric mean geometric mean ratio group groups had no healthy control healthy individuals heterologous vaccine homologous IBD Immunosuppressed immunosuppressed patient immunosuppressive Immunosuppressive treatment Infection Inflammatory bowel disease jak inhibitors multicentre multivariable nine no significant difference Older Older age participant Patient patients treated Pfizer Primary outcome receiving Receptor binding domain recipient recruited reduced regimen response S1 RBD SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 vaccination significantly significantly lower Support T-cell Response T-cell responses the healthy therapy Tofacitinib Treatment ulcerative colitis Vaccine vaccine dose vaccine doses vaccine-induced antibody response VIP were measured [DOI] 10.1016/S2468-1253(22)00274-6 PMC 바로가기
[Herpes Zoster Ophthalmicus after Pfizer BNT162b2 and Moderna mRNA-1273 vaccination in two young and immunocompetent patients]Article Published on 2022-11-012023-06-02 Journal: Journal français d'ophtalmologie [Category] SARS, 두창, 홍역, [키워드] coronavirus COVID-19 Effets secondaires Herpes Zoster Ophthalmicus Moderna Pfizer Side effects vaccination zona ophtalmique. [DOI] 10.1016/j.jfo.2022.09.004 PMC 바로가기
Post-vaccination COVID Toes (Chilblains) Exacerbated by Rituximab Infusion Suggests Interferon Activation as MechanismArticle Published on 2022-10-292022-11-15 Journal: Military Medicine [Category] 진단, [키워드] Activation acute respiratory syndrome adverse effect chilblains coronavirus COVID disease infusion interferon mechanism Pfizer presenting rituximab significantly skin lesion Toe Vaccine worsened [DOI] 10.1093/milmed/usab314 PMC 바로가기
Observational Study of Receptor Binding Domain Spike Antibody Responses to 3 SARS-CoV-2 Vaccinations in Noninfected Subjects: Parallel Neutralizing Antibody and Cardiac Troponin I and T ObservationsArticle Published on 2022-10-292022-11-15 Journal: The journal of applied laboratory medicine [Category] COVID19(2023년), SARS, 진단, [키워드] antibody Biotechnology blood specimen cardiac cardiac troponin change collected Concentration concentrations Decline dose doses Effectiveness ET Healthcare increase janssen kinetic Moderna myocardial injury Neutralizing observation Pfizer platform point-of-care postvaccination Protein Pylon 3D RBD Receptor binding domain response SARS-CoV-2 seronegative specimens spike subject subjects troponin vaccination Vaccinations Vaccine were measured [DOI] 10.1093/jalm/jfac053 PMC 바로가기